CoChat
Sign Up
Cited by 220Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related Diseasesinterferon and immune responses

The interferon-α signature of systemic lupus erythematosus

Open access
Obermoser, G., Pascual, V.·2010·Lupus
DOI 10.1177/0961203310371161PMC PMC3658279
Open this paper in CoChat — free account

Abstract

Systemic lupus erythematosus (SLE) is a prototypic multisystem autoimmune disorder where interplay of environmental and genetic risk factors leads to progressive loss of tolerance to nuclear antigens over time, finally culminating in clinical disease. The heterogeneity of clinical manifestations and the disease’s unpredictable course characterized by flares and remissions are very likely a reflection of heterogeneity at the origin of disease, with a final common pathway leading to loss of tolerance to nuclear antigens. Impaired clearance of immune complexes and apoptotic material and production of autoantibodies have long been recognized as major pathogenic events in this disease. Over the past decade the type I interferon cytokine family has been postulated to play a central role in SLE pathogenesis, by promoting feedback loops progressively disrupting peripheral immune tolerance and driving disease activity. The identification of key molecules involved in the pathogenesis of SLE will not only improve our understanding of this complex disease, but also help to identify novel targets for biological intervention. Lupus (2010) 19, 1012—1019.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0961203310371161

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many of the changes in the circulating proteome in people with Down syndrome are highly reminiscent of those observed in type I interferonopathies and other autoinflammatory conditions.

    “Our study of the circulating proteome in people with DS, the largest and most comprehensive study of this kind reported to date, reveals that T21 causes profound immune dysregulation, with many of the changes being highly reminiscent of those observed in type I interferonopathies and other autoinflammatory conditions54,58–60,88 (Table 1).”

    From Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) · cites this paper as [54]

    The section “The IFN-α signature of SLE” reports elevated interferon and upregulated interferon-regulated transcripts in the blood of people with lupus, supporting an analogy to interferon-associated immune changes. It does not examine the circulating proteome in Down syndrome or establish that its protein changes resemble those in lupus or other conditions. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 89

  1. [1]Rahman A Isenberg DA Systemic lupus erythematosus N Engl J Med 2008 358 929 939 18305268
  2. [2]Moser KL Kelly JA Lessard CJ Harley JB Recent insights into the genetic basis of systemic lupus erythematosus Genes Immun 2009 10 373 379 19440199 PMC3144759
  3. [3]Harley IT Kaufman KM Langefeld CD Harley JB Kelly JA Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies Nat Rev Genet 2009 10 285 290 19337289 PMC2737697
  4. [4]Gateva V Sandling JK Hom G A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus Nat Genet 2009 41 1228 1233 19838195 PMC2925843
  5. [5]Mathis D Benoist C Levees of immunological tolerance Nat Immunol 2010 11 3 6 20016503
  6. [6]Prokunina L Castillejo-Lopez C Oberg F A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans Nat Genet 2002 32 666 669 12402038
  7. [7]Graham RR Kyogoku C Sigurdsson S Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus Proc Natl Acad Sci U S A 2007 104 6758 6763 17412832 PMC1847749
  8. [8]Remmers EF Plenge RM Lee AT STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus N Engl J Med 2007 357 977 986 17804842 PMC2630215
  9. [9]Harley JB Alarcon-Riquelme ME Criswell LA Genomewide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci Nat Genet 2008 40 204 210 18204446 PMC3712260
  10. [10]Hom G Graham RR Modrek B Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX N Engl J Med 2008 358 900 909 18204098
  11. [11]Kozyrev SV Abelson AK Wojcik J Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus Nat Genet 2008 40 211 216 18204447
  12. [12]Nath SK Han S Kim-Howard X A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus Nat Genet 2008 40 152 154 18204448
  13. [13]Stetson DB Ko JS Heidmann T Medzhitov R Trex1 prevents cell-intrinsic initiation of autoimmunity Cell 2008 134 587 598 18724932 PMC2626626
  14. [14]Graham RR Hom G Ortmann W Behrens TW Review of recent genome-wide association scans in lupus J Intern Med 2009 265 680 688 19493061
  15. [15]Jacob CO Zhu J Armstrong DL Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus Proc Natl Acad Sci U S A 2009 106 6256 6261 19329491 PMC2669395
  16. [16]Cunninghame Graham DS Vyse TJ Fortin PR Association of LY9 in UK and Canadian SLE families Genes Immun 2008 9 93 102 18216865
  17. [17]Rieck M Arechiga A Onengut-Gumuscu S Greenbaum C Concannon P Buckner JH Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes J Immunol 2007 179 4704 4710 17878369
  18. [18]Arechiga AF Habib T He Y Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling J Immunol 2009 182 3343 3347 19265110 PMC2797545
  19. [19]Coxon A Rieu P Barkalow FJ A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation Immunity 1996 5 653 666 8986723
  20. [20]Arbuckle MR McClain MT Rubertone MV Development of autoantibodies before the clinical onset of systemic lupus erythematosus N Engl J Med 2003 349 1526 1533 14561795
  21. [21]Casciola-Rosen LA Anhalt G Rosen A Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes J Exp Med 1994 179 1317 1330 7511686 PMC2191465
  22. [22]Casciola-Rosen L Andrade F Ulanet D Wong WB Rosen A Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity J Exp Med 1999 190 815 826 10499920 PMC2195625
  23. [24]Brinkmann V Zychlinsky A Beneficial suicide: why neutrophils die to make NETs Nat Rev Microbiol 2007 5 577 582 17632569
  24. [25]Hirsch JG Bactericidal action of histone J Exp Med 1958 108 925 944 13598820 PMC2136925
  25. [26]Lu L Kaliyaperumal A Boumpas DT Datta SK Major peptide autoepitopes for nucleosome-specific T cells of human lupus J Clin Invest 1999 104 345 355 10430616 PMC408421
  26. [27]Michaels MA Kang HK Kaliyaperumal A Satyaraj E Shi Y Datta SK A defect in deletion of nucleosome-specific autoimmune T cells in lupus-prone thymus: role of thymic dendritic cells J Immunol 2005 175 5857 5865 16237078
  27. [28]Walport MJ Complement. Second of two parts N Engl J Med 2001 344 1140 1144 11297706
  28. [29]Manderson AP Botto M Walport MJ The role of complement in the development of systemic lupus erythematosus Annu Rev Immunol 2004 22 431 456 15032584
  29. [30]Harley JB Kelly JA Kaufman KM Unraveling the genetics of systemic lupus erythematosus Springer Semin Immunopathol 2006 28 119 130 17021721
  30. [31]Lood C Gullstrand B Truedsson L C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis Arthritis Rheum 2009 60 3081 3090 19790049
  31. [32]Vilcek J Fifty years of interferon research: aiming at a moving target Immunity 2006 25 343 348 16979566
  32. [33]Theofilopoulos AN Baccala R Beutler B Kono DH Type I interferons (alpha/beta) in immunity and autoimmunity Annu Rev Immunol 2005 23 307 336 15771573
  33. [34]Noppert SJ Fitzgerald KA Hertzog PJ The role of type I interferons in TLR responses Immunol Cell Biol 2007 85 446 457 17667935
  34. [35]van Boxel-Dezaire AHH Rani MRS Stark GR Complex modulation of cell type-specific signaling in response to type I interferons Immunity 2006 25 361 372 16979568
  35. [36]Preble OT Black RJ Friedman RM Klippel JH Vilcek J Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon Science 1982 216 429 431 6176024
  36. [37]Ronnblom LE Alm GV Oberg KE Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour J Intern Med 1990 227 207 210 1690258
  37. [38]Vallin H Blomberg S Alm GV Cederblad B Ronnblom L Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells Clin Exp Immunol 1999 115 196 202 9933442 PMC1905199
  38. [39]Vallin H Perers A Alm GV Ronnblom L Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus J Immunol 1999 163 6306 6313 10570325
  39. [40]Ronnblom L Alm GV A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus J Exp Med 2001 194 F59 F63 11748288 PMC2193578
  40. [41]Lovgren T Eloranta ML Bave U Alm GV Ronnblom L Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG Arthritis Rheum 2004 50 1861 1872 15188363
  41. [42]Siegal FP Kadowaki N Shodell M The nature of the principal type 1 interferon-producing cells in human blood Science 1999 284 1835 1837 10364556
  42. [43]Baechler EC Batliwalla FM Karypis G Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus Proc Natl Acad Sci U S A 2003 100 2610 2615 12604793 PMC151388
  43. [44]Bennett L Palucka AK Arce E Interferon and granulopoiesis signatures in systemic lupus erythematosus blood J Exp Med 2003 197 711 723 12642603 PMC2193846
  44. [46]Feng D Stone RC Eloranta ML Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus Arthritis Rheum 2010 62 562 573 20112383 PMC3213692
  45. [47]Palucka AK Banchereau J Blanco P Pascual V The interplay of dendritic cell subsets in systemic lupus erythematosus Immunol Cell Biol 2002 80 484 488 12225385
  46. [48]Banchereau J Pascual V Type I interferon in systemic lupus erythematosus and other autoimmune diseases Immunity 2006 25 383 92 16979570
  47. [49]Yao Y Richman L Higgs BW Neutralization of interferonalpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus Arthritis Rheum 2009 60 1785 1796 19479852
  48. [50]Ronnblom L Alm GV Eloranta ML Type I interferon and lupus Curr Opin Rheumatol 2009 21 471 477 19525849
  49. [51]Cella M Jarrossay D Facchetti F Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon Nat Med 1999 5 919 923 10426316
  50. [52]Liu YJ IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors Annu Rev Immunol 2005 23 275 306 15771572
  51. [54]Izaguirre A Barnes BJ Amrute S Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells J Leukoc Biol 2003 74 1125 1138 12960254
  52. [55]Honda K Ohba Y Yanai H Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction Nature 2005 434 1035 1040 15815647
  53. [56]Honda K Yanai H Negishi H IRF-7 is the master regulator of type-I interferon-dependent immune responses Nature 2005 434 772 777 15800576
  54. [57]Ronnblom L Pascual V The innate immune system in SLE: type I interferons and dendritic cells Lupus 2008 17 394 399 18490415 PMC3694565
  55. [58]Grouard G Rissoan MC Filgueira L Durand I Banchereau J Liu YJ The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand J Exp Med 1997 185 1101 1111 9091583 PMC2196227
  56. [59]Dzionek A Sohma Y Nagafune J BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction J Exp Med 2001 194 1823 1834 11748283 PMC2193584
  57. [60]Cederblad B Blomberg S Vallin H Perers A Alm GV Ronnblom L Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells J Autoimmun 1998 11 465 470 9802930
  58. [61]Blanco P Palucka AK Gill M Pascual V Banchereau J Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus Science 2001 294 1540 1543 11711679
  59. [62]Blomberg S Eloranta ML Cederblad B Nordlin K Alm GV Ronnblom L Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus Lupus 2001 10 484 490 11480846
  60. [63]Farkas L Beiske K Lund-Johansen F Brandtzaeg P Jahnsen FL Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions Am J Pathol 2001 159 237 243 11438470 PMC1850412
  61. [64]Tucci M Quatraro C Lombardi L Pellegrino C Dammacco F Silvestris F Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18 Arthritis Rheum 2008 58 251 262 18163476
  62. [65]Obermoser G Schwingshackl P Weber F Recruitment of plasmacytoid dendritic cells in ultraviolet irradiation-induced lupus erythematosus tumidus Br J Dermatol 2009 160 197 200 19016699
  63. [66]Napirei M Karsunky H Zevnik B Stephan H Mannherz HG Moroy T Features of systemic lupus erythematosus in Dnase1-deficient mice Nat Genet 2000 25 177 181 10835632
  64. [67]Botto M Dell’Agnola C Bygrave AE Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies Nat Genet 1998 19 56 59 9590289
  65. [68]Lande R Gregorio J Facchinetti V Chatterjee B Wang Y-h Homey B Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide Nature 2007 449 17873860
  66. [69]Tian J Avalos AM Mao SY Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE Nat Immunol 2007 8 487 496 17417641
  67. [70]Latz E Schoenemeyer A Visintin A TLR9 signals after translocating from the ER to CpG DNA in the lysosome Nat Immunol 2004 5 190 198 14716310
  68. [71]Bave U Magnusson M Eloranta ML Perers A Alm GV Ronnblom L Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG J Immunol 2003 171 3296 3302 12960360
  69. [72]Means TK Latz E Hayashi F Murali MR Golenbock DT Luster AD Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9 J Clin Invest 2005 115 407 417 15668740 PMC544604
  70. [73]Sano H Morimoto C DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content J Immunol 1982 128 1341 1345 7057035
  71. [74]Barrat FJ Meeker T Gregorio J Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus J Exp Med 2005 202 1131 1139 16230478 PMC2213213
  72. [75]Vollmer J Tluk S Schmitz C Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8 J Exp Med 2005 202 1575 1585 16330816 PMC2213330
  73. [76]Marshak-Rothstein A Toll-like receptors in systemic autoimmune disease Nat Rev Immunol 2006 6 823 835 17063184 PMC7097510
  74. [77]Savarese E Chae OW Trowitzsch S U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7 Blood 2006 107 3229 3234 16368889
  75. [78]Krieg AM Vollmer J Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity Immunol Rev 2007 220 251 269 17979852
  76. [79]Gilliet M Cao W Liu YJ Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases Nat Rev Immunol 2008 8 594 606 18641647
  77. [80]Barrat FJ Coffman RL Development of TLR inhibitors for the treatment of autoimmune diseases Immunol Rev 2008 223 271 283 18613842
  78. [81]Vollmer J Krieg AM Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Adv Drug Deliv Rev 2009 61 195 204 19211030
  79. [82]Rutz M Metzger J Gellert T Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner Eur J Immunol 2004 34 2541 2550 15307186
  80. [83]Lafyatis R York M Marshak-Rothstein A Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006 54 3068 3070 17009223
  81. [84]Banchereau J Briere F Caux C Immunobiology of dendritic cells Annu Rev Immunol 2000 18 767 811 10837075
  82. [85]Santini SM Lapenta C Logozzi M Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice J Exp Med 2000 191 1777 1788 10811870 PMC2193160
  83. [86]Ehrenstein MR Evans JG Singh A Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy J Exp Med 2004 200 277 285 15280421 PMC2211983
  84. [87]Blair PA Norena LY Flores-Borja F CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients Immunity 2010 32 129 140 20079667
  85. [88]Blanco P Pitard V Viallard JF Taupin JL Pellegrin JL Moreau JF Increase in activated CD8+T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus Arthritis Rheum 2005 52 201 211 15641052
  86. [89]Ganguly D Chamilos G Lande R Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 J Exp Med 2009 206 1983 1994 19703986 PMC2737167
  87. [90]Jego G Palucka AK Blanck JP Chalouni C Pascual V Banchereau J Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6 Immunity 2003 19 225 234 12932356
  88. [91]Leadbetter EA Rifkin IR Hohlbaum AM Beaudette BC Shlomchik MJ Marshak-Rothstein A Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors Nature 2002 416 603 607 11948342
  89. [92]Baccala R Hoebe K Kono DH Beutler B Theofilopoulos AN TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity Nat Med 2007 13 543 551 17479100

Cited by

Sorted by citations

Authors
Obermoser, G., & Pascual, V.
Affiliations
  • Innsbruck Medical University (AT)
  • Baylor Institute for Immunology Research, Dallas, TX, USA,
ORCID
Venue
Lupus
Publisher
SAGE Publications
Published
2010-08
Volume
19
Issue
9
Pages
1012-1019
ISSN
  • 0961-2033 (ISSN-L)
  • 1477-0962
DOI
10.1177/0961203310371161
PMC
PMC3658279
OpenAlex
W2117832897
Cited by
220
References
3
Citations by year
2026: 7 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 12 · 2020: 12 · 2019: 17 · 2018: 14 · 2017: 17 · 2016: 20 · 2015: 19 · 2014: 19 · 2013: 23 · 2012: 19
FWCI
2.41
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Lupus (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Allergy and Infectious Diseases (U19AI082715, U19-AI082715-01)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR050770, P50AR055503, P50AR054083, AR055503-01CORT, AR054083-01CORT)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Keywords
systemic lupus erythematosus, type I interferon, interferon signature, autoimmunity, immune tolerance, nuclear antigens, immune complexes, efferocytosis, autoantibodies, disease heterogeneity, SLE pathogenesis, therapeutic target
MeSH terms
Animals, Autoantibodies, Humans, Immune Tolerance, Interferon Type I, Lupus Erythematosus, Systemic, Interferon-alpha, Apoptosis, Antigens, Nuclear

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review